Novartis Plans Alzheimer’s Study in Symptomless Patients
This article is for subscribers only.
Novartis AG plans to test experimental drugs in a study to see whether the medicines can prevent Alzheimer’s in people without symptoms who are genetically predisposed to the disease.
In partnership with Banner Alzheimer’s Institute, a Phoenix, Arizona-based nonprofit, the Swiss drugmaker will test two drugs targeting the amyloid protein that builds up in the brains of people with Alzheimer’s. The trials will gauge the response of symptomless patients with two copies of the APoE4 gene that’s known to raise the risk for the disease.